<DOC>
	<DOC>NCT01112670</DOC>
	<brief_summary>The purpose of this study is to determine the pharmacogenetics, pharmacokinetics, and drug-drug interactions of sitagliptin therapy.</brief_summary>
	<brief_title>The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology</brief_title>
	<detailed_description />
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Healthy men and women between 21 to 60 years of age will be recruited to participate in this study. Subjects will be eligible if metabolic, renal, hepatic, and hematological laboratory tests are within normal limits. Subjects will be excluded from the study if they have a current or past history of cardiovascular, hepatic, endocrine (e.g., diabetes), renal, pancreatic, gastrointestinal, pulmonary, immunologic, hematologic, or neurologic disease.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Healthy volunteers</keyword>
</DOC>